2Gebbia V, Mantovani G, Agostara B, et al. Treatment of recurrent and /or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin and 5-fluorouracil: a multicenter phase Ⅱ trial[J].Ann Oncol, 1995, (6):987-991.
4Lee N, Xia P, Quivey JM, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeai carcinoma: an update of the UCSF experience[J]. Int J Radiat Oncol Biol Phys, 2002, 53(1):12-22.
5Baujat B, Audry G, Bourhis J, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients[J]. Int J Radiat Oncol Biol Phys, 2006, 64 (1):47-56.
6A1-Sarraf M, LeBlanc M, Gift PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer. Phase Ⅲ randomized intergroup study 0099 [J].J Clin Oncol, 1998, 16(4):1310-1317.
7Segura A, Pastor M, Santaballa A, et al. Cisplatin plus vinorelbine for patients with advanced head and neck squamous cell carcinoma[J]. Oncologist, 2000, 5(2): 177-178.
8Erjala K, Zhang N, Sundvall M, et al. Concomitant chemoirradiation with vinorelbine and gefitinib induces additive effect in head and neck squamous cell carcinoma cell lines in vitro[J]. Radiother Oncol,2007,85(1):138-145.
9Newby D, Hill S. Use of pharmacoeconomics in prescribing research, Part 2: cost - minimization analysis when are two therapies equal [ J ]. J Clin Pharm Ther,2003 ,28(2) :145 - 150.
10Cohen BJ. Discounting in cost - utility analysis of healthcare interventions: reassessing current practice [ J ]. Pharmacoeconomics ,2003,21 (2): 75 - 87.
